Safety and efficacy of eltrombopag in the treatment of children with immune thrombocytopenia: a Meta analysis.

OBJECTIVES:

To systematically assess the efficacy and safety of eltrombopag in the treatment of children with immune thrombocytopenia (ITP).

METHODS:

PubMed, Embase, Cochrane Library, Weipu Data, CNKI, and Wanfang Data were searched for studies on eltrombopag used for the treatment of children with ITP. RevMan 5.3 and R version 3.6 were used to perform a Meta analysis of included studies.

RESULTS:

A total of 11 studies were included, with 2 randomized controlled trials and 9 cohort studies. The Meta analysis of the 9 cohort studies showed that eltrombopag had a response rate of about 70% (95%CI: 65%-76%) in the treatment of children with ITP, with no serious adverse events. The Meta analysis of the randomized controlled trials showed that the eltrombopag group had a higher response rate than the placebo group (RR=2.64, 95%CI: 1.58-4.44, P<0.05), while there was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups (P>0.05).

CONCLUSIONS:

Eltrombopag has good efficacy and safety as a second-line treatment regimen for children with ITP.